-
Boao Lecheng Medical Tourism Zone Partners with Eye Valley to Advance Ophthalmology Innovation
•
The Boao Lecheng Medical Tourism Pilot Zone in Hainan Province has announced a strategic partnership with the Eye Valley in Wenzhou. This collaboration aims to promote the transformation of significant scientific and technological achievements in ophthalmology, attract high-level talent for innovation and entrepreneurship, and support the development of high-quality pharmaceutical…
-
Cellular Biomedicine Group Initiates Phase III Study for AlloJoin in Knee Osteoarthritis
•
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has announced the initiation of a Phase III clinical study for its allogeneic human adipose mesenchymal progenitor cell injection, AlloJoin. This follows a successful randomized, double-blind, controlled multi-center Phase II clinical study, which included a 96-week follow-up and preliminarily demonstrated a…
-
Abbisko Therapeutics Secures Orphan Drug Designation for FGFR4 Inhibitor ABSK012
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received orphan drug designation (ODD) status from the US Food and Drug Administration (FDA) for its next-generation FGFR4 mutant inhibitor, ABSK012, intended for the treatment of soft-tissue sarcoma. Preclinical Efficacy of ABSK012 Against FGFR4 MutantsPreclinical studies have…
-
Henlius Reports 91.1% Revenue Growth in 2022, Driven by Product Commercialization
•
China-based Henlius (HKG: 2696) has announced its annual results for 2022, revealing that revenues reached RMB 3.214 billion (USD 466.5 million), representing a remarkable increase of 91.1% year-on-year (YOY). This growth was driven by the successive commercialization of various products, with the company currently having launched five products in China…
-
Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates
•
China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key business updates. The company reported revenues of RMB 12.8 million (USD 1.86 million) for the year ending 31 December 2022, an increase of RMB 12.7 million (USD 1.84 million) compared to the previous year, primarily…
-
ClouDr Partners with Banbiantian to Digitalize Medicine and Medical Device Sector
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the name “ClouDr” (HKG: 9955), has entered into a strategic partnership with Wuhan Banbiantian Medical Technology Development Co., Ltd. The collaboration, which is centered around digitalization technologies, is designed to capitalize on the “medicine, device, drug” linkage model. While financial specifics…
-
Pharmaron Secures UK Government Grant to Expand Viral Vector Manufacturing Facility
•
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced the receipt of a substantial grant from the UK government’s Life Sciences Innovation Manufacturing Fund (LSMIF). The grant will facilitate the expansion of Pharmaron’s existing viral vector and DNA manufacturing facility in Liverpool,…
-
HutchMed Completes NDA Submission to US FDA for Frquintinib in Metastatic CRC
•
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its oral inhibitor of VEGFR-1, -2, and -3, fruquintinib. The drug is proposed for the treatment of refractory metastatic…
